LONDON--(BUSINESS WIRE)--May 16, 2017--
LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a
market-leading medical technology company, today announced Thad Huston
will join the Company as its new Chief Financial Officer (CFO),
effective May 20, 2017. LivaNova’s former CFO, Vivid Sehgal, is
coordinating with Huston to ensure an orderly transition. Huston will
report directly to Damien McDonald, Chief Executive Officer (CEO).
Huston is a highly strategic global finance executive who joins LivaNova
after more than 25 years at Johnson & Johnson (J&J), having most
recently served as Group Chief Financial Officer, Medical Devices. While
at J&J, Huston was pivotal in accelerating the growth for many of its
divisions through focused strategies, calculated investments in
innovation and streamlined productivity.
“I am pleased to welcome Thad Huston to LivaNova and to our Executive
Leadership Team as our new CFO,” said Damien McDonald, LivaNova CEO.
“Thad is equipped with a strong healthcare and medical device
background, coupled with the financial acumen and acuity to enhance our
strategic growth plans. I look forward to working together to drive
performance, build our pipeline and expand our portfolio in a
sustainable manner.”
During his tenure at J&J, Huston held various senior roles, including:
President of J&J’s Xian-Janssen Pharmaceuticals division in China; Vice
President – Finance, Chief Financial Officer and Chief Operations
Officer in J&J Pharmaceutical Research and Development; as well as Vice
President – Finance and Chief Financial Officer at Ortho-McNeil
Pharmaceuticals. Prior to this, he held senior financial roles at
various J&J locations in the U.S., China, Belgium, Russia and Hungary.
“I am eager to join the exceptional team at LivaNova,” said Huston. “We
share a passion for making a difference in patients’ lives, while
focusing on growth that will lead us to even greater success as a
company.”
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five
decades of experience and a relentless commitment to improve the lives
of patients around the world. LivaNova’s advanced technologies and
breakthrough treatments provide meaningful solutions for the benefit of
patients, healthcare professionals and healthcare systems. Headquartered
in London and with a presence in more than 100 countries worldwide, the
company employs more than 4,500 employees. LivaNova operates as three
business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm
Management, with operating headquarters in Mirandola
(Italy), Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit www.LivaNova.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170516005331/en/
Source: LivaNova PLC
LivaNova PLC Investor Relations and Media
Karen King, +1
281-228-7262
Vice President, Investor Relations & Corporate
Communications
or
Deanna Wilke, +1 281-727-2764
Corporate
External Communications Manager
Corporate.Communications@LivaNova.com